Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Wielenga

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|October 16, 1982
[Von Willebrand's disease]J J Wielenga, H L Haak
Nederlands Tijdschrift Voor Geneeskunde|December 1, 1984
[Malabsorption in lambliasis]J J Wielenga, A Berghout, S J Smith
Anti-Cancer Drugs|May 1, 1993
Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignanciesB Löwenberg, G E de Greef, J J Wielenga
Leukemia|January 1, 1996
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II studyJ J Wielenga, E Vellenga, A Groenewegen, et al.
The Netherlands Journal of Medicine|August 1, 1988
Non-Hodgkin's lymphoma of the corpus vitreumW Sizoo, J G van Andel, G S Baarsma, et al.
Progress in Clinical and Biological Research|January 1, 1990
Factors influencing reconstitution by bone marrow transplantationD W van Bekkum, J J Wielenga, F van Gils, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 2, 1995
[A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin]M H Silbermann, I C Gyssens, J J Wielenga, et al.
The Netherlands Journal of Medicine|January 12, 1999
Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and BelgiumE P Mauser-Bunschoten, A de Goede-Bolder, J J Wielenga, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1990
Interleukin-3G Wagemaker, H Burger, F C van Gils, et al.
Blood|March 15, 1996
Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemiaW Terpstra, A Prins, R E Ploemacher, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|October 16, 1982
[Von Willebrand's disease]J J Wielenga, H L Haak
Nederlands Tijdschrift Voor Geneeskunde|December 1, 1984
[Malabsorption in lambliasis]J J Wielenga, A Berghout, S J Smith
Anti-Cancer Drugs|May 1, 1993
Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignanciesB Löwenberg, G E de Greef, J J Wielenga
Leukemia|January 1, 1996
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II studyJ J Wielenga, E Vellenga, A Groenewegen, et al.
The Netherlands Journal of Medicine|August 1, 1988
Non-Hodgkin's lymphoma of the corpus vitreumW Sizoo, J G van Andel, G S Baarsma, et al.
Progress in Clinical and Biological Research|January 1, 1990
Factors influencing reconstitution by bone marrow transplantationD W van Bekkum, J J Wielenga, F van Gils, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 2, 1995
[A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin]M H Silbermann, I C Gyssens, J J Wielenga, et al.
The Netherlands Journal of Medicine|January 12, 1999
Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and BelgiumE P Mauser-Bunschoten, A de Goede-Bolder, J J Wielenga, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1990
Interleukin-3G Wagemaker, H Burger, F C van Gils, et al.
Blood|March 15, 1996
Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemiaW Terpstra, A Prins, R E Ploemacher, et al.
Pageof 3